Stockreport

BEACON Trial Data Makes Beam Therapeutics (BEAM) an Attractive Buy [Yahoo! Finance]

Beam Therapeutics Inc.  (BEAM) 
PDF Wainwright analyst Patrick Trucchio reaffirmed his bullish stance on Beam Therapeutics (NASDAQ:BEAM). He rated the stock Buy with a target price of $80, implying a subst [Read more]